Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02240498 · ClinicalTrials.gov registry record · Phase 1
Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities
A Phase 1 study of Abscess, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02240498: Completed Phase 1 study of Abscess, sponsored by University of Rochester.
NCT02240498 is a Phase 1 study of Abscess that has completed, run by University of Rochester. The registered enrollment target is 21 participants, below the 388-participant average among 13 other Abscess trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02240498, a Phase 1 study of Abscess, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this Phase 1 study are to evaluate the safety and feasibility of methylene-blue-mediated photodynamic therapy (MB-PDT) performed at the time of abscess drainage to treat deep tissue abscesses. Safety will be evaluated by physical examination and imaging and laboratory studies in order to identify adverse events that may be induced by MB-PDT. We hypothesize that MB-PDT will be a safe and feasible intervention for this patient population. Optical measurements will additionally be performed at the abscess wall to determine optical properties and methylene blue uptake.
Conditions Studied
Interventions
- DRUG Methylene Blue
- DRUG 20% I.V. Fat Emulsion
- DEVICE Insertion of optical fiber
- DEVICE Laser illumination, 5 minutes
- DEVICE Laser illumination, 10 minutes
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-09 |
| Est. Completion | 2023-09 |
| Phase | Phase 1 |
What the finished NCT02240498 record still lists
NCT02240498 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 388-participant average among 13 other Abscess trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Abscess appearing as the primary indexed condition, and to 5 interventions - of which Methylene Blue is the first listed.
NCT02240498 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02240498 about?
NCT02240498 is a clinical study titled "Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities". The objectives of this Phase 1 study are to evaluate the safety and feasibility of methylene-blue-mediated photodynamic therapy (MB-PDT) performed at the time of abscess drainage to treat deep tissue abscesses. Safety will be evaluated by physical examination and imaging and laboratory studies in or...
What is the current status of trial NCT02240498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2014-09. Estimated completion is 2023-09.
What conditions does trial NCT02240498 study?
This clinical trial studies the following conditions: Abscess.
What interventions are being tested in trial NCT02240498?
The interventions under investigation include: Methylene Blue (DRUG), 20% I.V. Fat Emulsion (DRUG), Insertion of optical fiber (DEVICE), Laser illumination, 5 minutes (DEVICE), Laser illumination, 10 minutes (DEVICE).
Who is sponsoring clinical trial NCT02240498?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02240498 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Abscess
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02240498's enrollment target sits among peer trials
21 13th of 13 higher than 1 of 13 other Abscess trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Abscess trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine as a Supplement to Local Anesthesia for Minor Procedures
RECRUITING · Phase 4
-
Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children
COMPLETED · Phase 3
-
Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage
COMPLETED · Phase 2
-
Adjunctive Nitrous Oxide During Emergency Department Propofol Sedation in Adults
COMPLETED · NA
-
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
COMPLETED · NA
-
Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia